Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    Conference Program for 2022 the World Conference on Lung Cancer

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2137

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    IBS05 - Controversies in Management of Locally Advanced NSCLC (Ticketed Session) (In-person Access Only)

    • 07:30 - 08:15
    • 8/07/2022
    • Location: Strauss 1/2
    • IASLC CME Accredited
    • Type: Interactive Breakfast Session
    • Track: Locally Advanced Non-small Cell Lung Cancer
    • +

      IBS05.01 - Controversies in Management of Locally Advanced NSCLC

      07:30 - 07:45  |  Presenter: Gerard G Hanna

      • Abstract

      Loading...

  • +

    EP05.01 - Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy
    • +

      EP05.01-007 - CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC)

      Presenter: Gerard M Walls

      • Abstract

      Loading...

    • +

      EP05.01-023 - Feasibility of Functional Lung Avoidance using Ga-68 4D Ventilation Perfusion PET/CT: The HI-FIVE Trial

      Presenter: Nicholas Wentworth Bucknell

      • Abstract

      Loading...

  • +

    EP08.03 - Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease
    • +

      EP08.03-005 - HALT - Targeted Therapy with or without Dose-Intensified Radiotherapy in Oligo-Progressive Disease in Oncogene Addicted Lung Tumours

      Presenter: Fiona McDonald

      • Abstract

      Loading...

  • +

    P1.10 - Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

    • 17:00 - 19:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: Regular Poster
    • Track: Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy
    • +

      P1.10-02 - ImmunoPET: A Phase 0/1 Study Characterising PD-L1 with 89Zr-Durvalumab (MEDI4736) PET/CT in Stage III NSCLC Patients Receiving Chemoradiation

      Presenter: Fiona Hegi-Johnson

      • Abstract

      Loading...

    • +

      P1.10-03 - A Deep Learning Auto-Segmentation Tool for Cardiac Substructures in 4D Radiotherapy Planning for Locally Advanced Lung Cancer

      Presenter: Gerard M Walls

      • Abstract

      Loading...

  • +

    MA09 - Palliative Radiotherapy: The Changing Landscape with Immunotherapy and Targeted Therapies

    • 14:45 - 15:45
    • 8/08/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Mini Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy
    • +

      MA09.05 - Increased PD-L1 Tracer Uptake in Recently-irradiated Lesions in NSCLC: Preliminary Results of a Phase 0 Trial (ImmunoPET) of a Novel PET Tracer

      14:57 - 15:02  |  Presenter: Michael Patrick MacManus

      • Abstract

      Loading...

  • +

    P2.03 - Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy

    • 17:15 - 19:15
    • 8/08/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: Regular Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy
    • +

      P2.03-01 - Initial Biodistribution Data of ImmunoPET A Phase 0/1 Study Characterising PD-L1 with 89 Zr-Durvalumab (MEDI4736) PET/CT

      Presenter: Fiona Hegi-Johnson

      • Abstract

      Loading...